AYLo study–elevated relapse risk and dysregulated proinflammatory signalling in giant cell arteritis patients with mosaic loss of the Y chromosome
Open Access
- 15 July 2025
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (11) , 1900-1908
Abstract
No abstract availableKeywords
Funding Information
- Multiple System Atrophy Coalition
This publication has 53 references indexed in Scilit:
- The giant cell arteritis (GCA) ultrasound score (OGUS) at diagnosis and after initial treatment predicts future relapses in GCA patients: results of a multicentre prospective studyAnnals of the Rheumatic Diseases, 2025
- Association of Somatic TET2 Mutations With Giant Cell ArteritisArthritis & Rheumatology, 2024
- The role of autoimmunity and autoinflammation in giant cell arteritis: A systematic literature reviewAutoimmunity Reviews, 2023
- Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical PopulationJAMA, 2023
- TET2-Driven Clonal Hematopoiesis and Response to CanakinumabJAMA Cardiology, 2022
- Utility of serological biomarkers for giant cell arteritis in a large cohort of treatment-naïve patientsClinical Rheumatology, 2018
- Polymyalgia Rheumatica and Giant Cell ArteritisJAMA, 2016
- Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer DiseaseThe American Journal of Human Genetics, 2016
- Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin‐6) in the long‐term followup of patients with giant cell arteritisArthritis Care & Research, 2010
- Correlation of interleukin‐6 production and disease activity in polymyalgia rheumatica and giant cell arteritisArthritis & Rheumatism, 1993